Drug intelligence / Profile preview

toripalimab + cyclophosphamide + doxorubicin + vincristine + ifosfamide + etoposide

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of toripalimab (a PD-1 blocking monoclonal antibody) with multiple chemotherapy agents including cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline), vincristine (a vinca alkaloid), ifosfamide (an alkylating agent), and etoposide (a topoisomerase inhibitor). This specific combination is not well-documented in the literature as a standard regimen.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on toripalimab + cyclophosphamide + doxorubicin + vincristine + ifosfamide + etoposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on toripalimab + cyclophosphamide + doxorubicin + vincristine + ifosfamide + etoposide.

Explore the full profile